Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02955602
Other study ID # CB8025-21629
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 28, 2016
Est. completion date July 8, 2019

Study information

Verified date June 2022
Source CymaBay Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)


Description:

Primary: To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of treatment Secondary: To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of treatment To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment To evaluate the pharmacokinetics (PK) of MBX-8025 Exploratory: To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and renal function MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date July 8, 2019
Est. primary completion date September 7, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Must have given written informed consent (signed and dated) and any authorizations required by local law 2. 18 to 75 years old (inclusive) 3. Male or female with a diagnosis of PBC, by at least two of the following criteria: - History of AP above ULN for at least six months - Positive AMA titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies - Documented liver biopsy result consistent with PBC 4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to UDCA 5. AP = 1.67 × ULN 6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose Exclusion Criteria: 1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment) 2. AST or ALT > 3 × ULN 3. Total bilirubin > 2.0 mg/dL 4. Total bilirubin > ULN AND albumin < LLN with the exception to subjects with Gilbert's Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin > ULN. 5. Auto-immune hepatitis 6. Primary sclerosing cholangitis 7. Known history of alpha-1-Antitrypsin deficiency 8. Known history of chronic viral hepatitis 9. Creatine kinase above ULN 10. Serum creatinine above ULN 11. For females, pregnancy or breast-feeding 12. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening 13. Current use of fibrates or simvastatin 14. Current use of obeticholic acid 15. Use of an experimental or unapproved treatment for PBC 16. Use of experimental or unapproved immunosuppressant 17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study (CB8025-21528) 18. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

Study Design


Intervention

Drug:
MBX-8025 2 mg Capsule
Initial 8-week treatment: • MBX-8025 2 mg Extension: The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed. Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
MBX-8025 5 mg Capsule
Initial 8-week treatment: • MBX-8025 5 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.
MBX-8025 10 mg Capsule
Initial 8-week treatment: • MBX-8025 10 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.

Locations

Country Name City State
Canada University of Calgary Liver Unit Calgary Alberta
Canada Toronto Centre for Liver Disease Toronto Ontario
Germany Outpatient Clinic of Internal Medicine Berlin
Germany University Hospital Erlangen Erlangen
Germany Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg Hamburg
Germany Center of Internal Medicine - Medical School of Hannover Hannover
Germany University Medical Centre of the Johannes Guttenberg-University Mainz
Germany Universitatsklinikum Giessen und Marburg GmbH Marburg
Germany Medizinische Universitatsklinik Tubingen Tubingen
United Kingdom University Hospitals Birmingham Birmingham
United Kingdom Cambridge University Hospitals NHS Foundation Trust Cambridge
United Kingdom Hull and East Yorkshire Hospitals NHS Trust Hull
United Kingdom Royal Free London NHS Foundation Trust London
United Kingdom Plymouth Hospitals NHS Trust Plymouth
United Kingdom Portsmouth Hospitals NHS Trust Portsmouth
United States Atlanta Gastroenterology Associates, LLC Atlanta Georgia
United States Digestive Healthcare of Georgia Atlanta Georgia
United States Mercy Medical Center Baltimore Maryland
United States Northest Clinical Research Center, LLC. Bethlehem Pennsylvania
United States Institute for Liver Health Chandler Arizona
United States Northwestern University Chicago Illinois
United States Southern California Research Center Coronado California
United States UT Southwestern Medical Center Investigation Drug Service Dallas Texas
United States Baylor College of Medicine Houston Texas
United States University of Mississippi Medical Center Jackson Mississippi
United States Florida Research Institute Lakewood Ranch Florida
United States Gastroenterology Consultants of SA Live Oak Texas
United States Northwell Health - Center for Liver Disease and Transplantation Manhasset New York
United States University of Miami - Center for Liver Diseases Miami Florida
United States NYU Langone Medical Center New York New York
United States The Mount Sinai Medical Center New York New York
United States Bon Secours St. Mary's Immaculate Hospital Newport News Virginia
United States Henry Ford Health System Novi Michigan
United States Standford University Medicine Palo Alto California
United States University of California, Davis Medical Center Sacramento California
United States Saint Louis University, Gastroenterology & Hepatology Saint Louis Missouri
United States University of Washington Seattle Washington
United States Ventura Clinical Trials Ventura California

Sponsors (1)

Lead Sponsor Collaborator
CymaBay Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 Relative change from baseline in serum ALP levels at Week 8 (endpoint). The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. n, denotes number of subjects evaluable for the respective timepoints 8 weeks
Secondary Absolute Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 12 and Week 52 Absolute change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Change in Aspartate Aminotransferase (AST) From Baseline to 12 Weeks and 52 Weeks Change from baseline in AST levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Change in Alanine Aminotransferase (ALT) From Baseline to 12 Weeks and 52 Weeks Change from baseline in ALT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Change in Gamma-glutamyl Transferase (GGT) From Baseline to 12 Weeks and 52 Weeks Change from baseline in GGT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Change in Bilirubin - Total Bilirubin (TB) From Baseline to 12 Weeks and 52 Weeks Change from baseline in TB levels at endpoint is being reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Percentage of Participants Meet Composite Endpoint Criteria of ALP and Total Bilirubin Participant meets composite endpoint is defined by participant meets all of the following criteria:
ALP < 1.67 × upper limit of normal (ULN)
Total Bilirubin within normal limit
> 15% decrease in ALP
Endpoint of Alkaline Phosphatase and Total Bilirubin by Visit (mITT Population)
12 Weeks and 52 Weeks
Secondary Percentage of Participants Meet Published PBC Response Criteria - Paris I Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (=) 3x ULN and aspartate aminotransferase (AST) less than or equal to (=) 2 x ULN and Total Bilirubin = 1 mg/dL.
The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
12 weeks and 52 weeks
Secondary Percentage of Participants Meet Published PBC Response Criteria - Paris II Percentage of participants with response based on Paris II risk score was defined as ALP=1.5xULN and AST=1.5xULN and Total Bilirubin = 1 mg/dL.
The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
12 weeks and 52 weeks
Secondary Percentage of Participants Meet Published PBC Response Criteria - Toronto I Percentage of participants with response based on Toronto I risk score defined as ALP = 1.67 x ULN. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary UK-PBC Risk Score Value The UK-PBC Risk Score at endpoint is defined by the mean percentage risk that a PBC patient treated with ursodeoxycholic acid (UDCA) would develop liver failure requiring liver transplantation in 5, 10 and 15 years from diagnosis. The higher the score might indicate higher risk to death or live transplantation. Formula used for UK-PBC risk score = 1- 0.982 ^EXP(0.0287854*(ALP12 x ULN-1.722136304) - 0.0422873*(((TA12 xULN/10)^-1) - 8.675729006) + 1.4199 * (LN(BIL12 x ULN/10)+2.709607778)-1.960303*(Albumin x LLN-1.17673001)-0.4161954*(Platelet x LLN-1.873564875)). Where, Baseline survivor function = 0.982, 0.941, and 0.893 for 5 years, 10 years and 15 years respectively. ALP12, TA12 and BIL12 refers to the ALP, transaminases (ALT, AST), and total bilirubin assessments, respectively. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Change From Baseline in Pruritus Visual Analog Score (VAS) at Week 12 and Week 52 VAS is the commonly used graphic tool for self-reporting of pruritus intensity in patients. VAS is a simple to use, validated, reliable and widely applicable tool that does not determine the impact of pruritus to quality of life. It comprises of a 100-mm horizontal line labelled as "no symptom" on left end and "worst imaginable symptom" on right end. Based on the intensity of the itch patient is instructed to draw a vertical line on the horizontal scale having a range [VAS values (unit: mm) ranging from 0 to 100, where 0 represents "no itching" and 100 "worst possible itching"].
The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.
12 weeks and 52 weeks
Secondary Change From Baseline in PBC-40 Quality of Life (QoL) at Week 12 and Week 52 The PBC-40 QoL questionnaire is a disease-specific health-related tool developed for measuring the psychometric profile in PBC patients. It has 10 domains and 43 questions relevant to PBC, including Cognitive, Social, Emotional Function, Fatigue, Itch, and Other Symptoms. Questions in domains: 1) digestion and diet (questions 1-3); 2) experiences (questions 4-7); 3) itching (questions 8-10); 4) fatigue (questions 11-18); 5) effort and planning (questions 19-21); 6) memory and concentration (questions 22-27); 7) affects to you as person (questions 28-33); 8) affects to your social life (questions 34-37); 9) overall impact on your life (questions 38-40); 10) general health and well-being (questions A-C). Within a domain, items are scored from 1 to 5 and the individual item scores are summed to give a total domain score. High scores represent high impact and low scores low impact of PBC on QoL (mITT Population). 12 weeks and 52 weeks
Secondary Percentage of Participants Meet Published PBC Response Criteria - Barcelona Percentage of participants with response based on Barcelona risk scores was defined as Normalization of ALP or a Decrease of ALP = 40%. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Absolute Change in MELD Score From Baseline to 12 Weeks and 52 Weeks Change from baseline to 12 weeks and 52 weeks in Model for End-stage Liver Disease (MELD) Score (mITT Population) The MELD score ranges from 6 to 40 and is a measure of how severe a patient's liver disease is. The higher the score, the more likely the patients will need a liver transplant. A calculated prognostic risk factor used to assess the potential need for a liver transplant.
MELD(i) score = 10*[0.957*ln(creatinine mg/dL) + 0. 378*ln(total bilirubin mg/dL) + 1.120*ln (INR) + 0.643].
If MELD(i) is less than or equal to 11 then MELD = MELD(i). If MELD(i) is greater than 11 then MELD = MELD(i) + (1.32 *(137 - (Na)) - (0.033*MELD(i)*(137 - Na))
12 weeks and 52 weeks
Secondary Change in GLOBE PBC Score From Baseline to 12 Weeks and 52 Weeks Change from Baseline to 12 weeks and 52 weeks in Global PBC Study Group (GLOBE) score (mITT Population)
The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation:
GLOBE score = (0.044378 * age + 0.93982 * LN(total bilirubin/ULN) +(0.335648 * LN(alkaline phosphatase/ULN)) - 2.266708 * albumin /LLN -0.002581 * platelet count per 109/L) + 1.216865
12 weeks and 52 weeks
Secondary Participants Meet Rotterdam Criteria participants with Response Based on Rotterdam Criteria at Weeks 12 and 52 Rotterdam Published PBC Response Criteria by Visit (mITT Population) Rotterdam criteria: Early (normal total bilirubin and normal albumin), Moderately advanced (either abnormal albumin or abnormal total bilirubin), and Advanced (both abnormal albumin and abnormal total bilirubin). From Early stage to Moderate Stage and to Advanced Stage, it becomes worse and worse in abnormality. 12 weeks and 52 weeks
Secondary Percentage of Participants Meet Composite Endpoint of AP and Total Bilirubin Criteria at Week 12 and Week 52 Percentage of participants with Response Defined by Composite Endpoint (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] within Normal Limits at Endpoint, and Greater Than Equal To [=] 15% ALP Reduction) from Baseline to Week 12 and Week 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
Secondary Percent Change in Serum Alkaline Phosphatase (ALP) Percent change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. 12 weeks and 52 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526665 - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) Phase 3
Recruiting NCT02931513 - sCD163 in PBC Patients - Assessment of Treatment Response
Active, not recruiting NCT02924701 - sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Completed NCT02659696 - Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
Completed NCT02078882 - Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Phase 4
Completed NCT01389973 - A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid Phase 2
Completed NCT01603199 - High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis N/A
Completed NCT01857284 - Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis Phase 3
Completed NCT05374200 - Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC) N/A
Recruiting NCT02937012 - Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Phase 3
Completed NCT02376335 - B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis Phase 2
Recruiting NCT01662973 - Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Phase 1/Phase 2
Active, not recruiting NCT04751188 - A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis Phase 3
Recruiting NCT04514965 - Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Recruiting NCT03668145 - Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis N/A
Completed NCT02557360 - Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Phase 4
Recruiting NCT01440309 - Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis Phase 1
Completed NCT01249092 - Pentoxifylline for Primary Biliary Cirrhosis Phase 2
Completed NCT01510860 - Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Phase 4
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2